The European Medicines Agency (EMA) has updated its guidance on nitrosamine impurities in human medicinal products, amending Q&A 10 and adding three appendices.
Following the European Pharmacopoeia (Ph. Eur.)’s revision of two major general monographs: Substances for pharmaceutical use (2034) and Pharmaceutical preparations (2619), revised in January 2023, the European Pharmacopoeia Commission (EPC) reviewed its current approaches, considering both current texts on N-nitrosamines, including general monographs 2034 and 2619. These texts are included in a corresponding statement in Supplement 11.3, which was recently published.
In the EPC’s 176th session on 20 and 21 June 2023, members decided to review the original strategy for N-nitrosamine control in individual monographs on active substances as well as medicinal products.
Explore innovative, purpose-built AI solutions that elevate compliance and efficiency in quality and manufacturing operations.
17 September 2025 | 10:00 AM BST | FREE Webinar
In this webinar, find out how AI tools such as customised large language models (LLMs), orchestrated services, and human-in-the-loop design can streamline processes, enhance training, and improve efficiencies.
Deleting the Production section covering N-nitrosamine impurities from individual monographs on active substances. The EPC also suggested not including these statements in future new monographs. The reasoning was that the general requirement for N-nitrosamines in the revised general monograph 2034 applies to all ingredients applicable to the text. Particularly, this would “prevent unnecessary repetition, ensure inter-monograph consistency and also prevent the absence of such a statement in a monograph being misinterpreted as an absence of risk”
To improve clarity, the EPC also suggested that clear rules are needed to define when to add a specification for N-nitrosamine impurities in the Tests section of an active substance monograph. In the meeting, it was suggested this should apply “only when the N-nitrosamine is a process-related impurity, ie, generated during synthesis of the substance, or a degradation impurity arising from its storage”.
Additionally, it was suggested that the “test and limit would be included in an individual monograph if the impurity has been detected in several sources of the substance and once a limit approved by competent authorities or recommended by the Non-clinical Working Party (NcWP) becomes available”.
Updated guidance on nitrosamine impurities
On 7 July 2023, the European Medicines Agency (EMA) updated its guidance on nitrosamine impurities.
The regulatory body has amended Q&A 10 to include the Carcinogenic Potency Categorization Approach (CPCA) and the enhanced Ames test (EAT) for establishing acceptable intakes (AIs) for N-nitrosamines.
The assessment report of the Committee for Medicinal Products for Human Use (CHMP)’s Article 5(3) of Regulation (EC) No 726/2004 opinion on nitrosamine impurities in human medicinal products offers guidance and recommendations on mitigation and prevention of nitrosamine-contaminated human medicinal products.
What else is included in the EMA’s revised guidance on nitrosamine impurities?
Included in the revision is the addition of Appendix 1. It lists the nitrosamines for which AI have been established by the Non-clinical Working Party (NcWP), including new AIs for N-nitrosamines determined using the CPCA.
Also added was Annex 2, which describes the CPCA for N-nitrosamines.
The guidance on nitrosamine impurities also has addition to Annex 3. It describes the Enhanced Ames Test Conditions for N-nitrosamines.
EMA highlighted that the enhanced Ames assay test conditions are informed by work conducted by groups such as the US Food and Drug Administration (FDA)’s National Center for Toxicological Research (NCTR) and have been evaluated for a variety of N-nitrosamines including NDSRIs.
Evaluation of Ames assay test conditions for N-nitrosamines is ongoing, with a goal to identify the most robust Ames testing conditions, EMA reported in the revision document. Deviations from the recommended conditions should be justified.
Limiting nitrosamines in human medicines
All MAHs/Applicants of human medicinal products must work with their active pharmaceutical ingredient (API) and finished product (FP) manufacturers to ensure presence of nitrosamine impurities is mitigated and controlled, according to EMA. This effort should be implemented as much as possible at or below a limit defined based on ICH M7(R1) principles for substances of the “cohort of concern” reflected in the EMA’s updated guideline. It should be calculated considering a lifetime daily exposure and kept as low as possible and that appropriate risk mitigating measures are taken, EMA stated.
Interested parties should share comments on the proposed strategy via the EDQM HelpDesk by the end of September 2023. The EPC will make a final decision on its strategy for N-nitrosamine impurities in individual monographs at its session in November 2023.
The original news piece was published on 10 July 2023, with additional details added on 24 July 2023.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.